AstraZeneca Covid-19 vaccine trial volunteer dies
A volunteer for a Covid-19 vaccine clinical trial in Brazil has died. But he never actually received the experimental vaccine, although he was involved in the trial groups. He did, however, die of Covid-19.
But trials on the vaccine, being developed by Oxford University and the pharmaceutical company AstraZeneca, are set to continue. The university says “there have been no concerns about safety of the clinical trial.” The vaccine is also planned to be produced in Thailand and be available to the Thai population by the first half of 2021.
The 28 year old volunteer from Rio de Janeiro died from Covid-19 complications, according to CNN Brasil. He was apparently never injected with the experimental vaccine. If the volunteer had been given the Covid-19 vaccine and died, the trial would have been suspended, a source told Reuters, adding that the volunteer may have been part of the control group.
The Federal University of Sao Paulo is helping to coordinate the trials in Brazil and has also recommended the trials continue. So far, 8,000 volunteers have been injected with the first dose of the vaccine and some have already been jabbed a second time, a university spokesperson said.
“Everything is proceeding as expected, without any record of serious vaccine-related complications involving any of the participating volunteers.”
Thailand is set to be the Southeast Asia production site for the new vaccine. If the AstraZeneca trials are successful, the vaccine will be available to the Thai population by the first half of 2021. For Thailand, the vaccine is seen as a lifeline to save the country’s struggling economy, allowing borders to safely reopen and revive the tourism industry.
The company Siam Bioscience will manufacture the vaccine in Thailand and provide injections for the Thai populations as well as the neighbouring countries Indonesia, Singapore, Malaysia, Philippines, Vietnam, Brunei, Cambodia, Myanmar and Laos.
SOURCE: Thai PBS
Covid-19 NewsWorld NewsLeave a Reply
You must be logged in to post a comment.